KCM
ADPT icon

Kennedy Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Kennedy Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Sell
849,795
-81,727
-9% -$1.25M 0.32% 89
2026
Q1 		$12.9M Buy
931,522
+31,291
+3% +$499K 0.27% 133
2025
Q4 		$14.6M Sell
900,231
-373,415
-29% -$6.09M 0.31% 112
2025
Q3 		$19.1M Sell
1,273,646
-24,257
-2% -$296K 0.42% 52
2025
Q2 		$15.1M Buy
1,297,903
+29,329
+2% +$266K 0.36% 72
2025
Q1 		$9.43M Buy
+1,268,574
New +$9.75M 0.23% 152

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kennedy Capital Management's ADPT Position: Q2 2026 in Review

Kennedy Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 8.8% in Q2 2026, selling an estimated $1.25M and leaving 849,795 shares worth $18.2M. The position accounts for 0.32% of the portfolio, ranked #89.

Kennedy Capital Management first reported a position in ADPT in Q1 2025 and has held it in 6 quarters since. The position peaked at $19.1M in Q3 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Kennedy Capital Management held 849,795 shares of Adaptive Biotechnologies worth $18.2M as of Q2 2026.
  • Kennedy Capital Management sold 81,727 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.25M.
  • Adaptive Biotechnologies made up 0.32% of Kennedy Capital Management's portfolio in Q2 2026, its #89 holding.
  • Kennedy Capital Management first reported a position in Adaptive Biotechnologies in Q1 2025 and has held it in 6 quarters since.
  • Kennedy Capital Management's Adaptive Biotechnologies position peaked at $19.1M in Q3 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.